Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01516580 |
Recruitment Status : Unknown
Verified June 2017 by Gustave Roussy, Cancer Campus, Grand Paris.
Recruitment status was: Active, not recruiting
First Posted : January 25, 2012
Last Update Posted : June 14, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
B-cell Non Hodgkin Lymphoma Mature B-cell Leukemia Burkitt-type | Drug: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C Drug: Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 482 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial |
Study Start Date : | December 2011 |
Actual Primary Completion Date : | June 13, 2017 |
Estimated Study Completion Date : | December 2021 |
Arm | Intervention/treatment |
---|---|
Active Comparator: LMB chemo
Prephase (COP) for all groups followed by:
|
Drug: Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
Prephase (COP) for all groups followed by: in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses. |
Experimental: LMB chemo + Rituximab
LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
|
Drug: Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE). |
- Event free survival [ Time Frame: 24 months ]Minimum time to death from any cause, presence of viable cells in residue after [2nd (Rituximab-)CYVE], relapse, progressive disease, or second malignancy measured from randomization.
- Survival [ Time Frame: 5 years ]Overall survival
- Acute toxicity [ Time Frame: 6 months ]Acute toxicity during treatment according to NCI-CTC V4
- Long term toxicity [ Time Frame: 5 years ]Long term toxicity, especially immune reconstitution, cardiac toxicity
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Months to 17 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically or cytologically proven B-cell malignancies, either Burkitt lymphoma or B-AL (=Burkitt leukaemia = L3-AL) or diffuse large B-cell NHL or aggressive mature B-cell NHL non other specified or specifiable.
- Stage III with elevated LDH level ("B-high"), [LDH > twice the institutional upper limit of the adult normal values (> Nx2)] or any stage IV or B-AL.
- 6 months to less than 18 years of age at the time of consent.
- Males and females of reproductive potential must agree to use an effective contraceptive method during the treatment, and after the end of treatment: during twelve months for women, taking into account the characteristics of rituximab and during five months for men, taking into account the characteristics of methotrexate.
- Complete initial work-up within 8 days prior to treatment that allows definite staging.
- Able to comply with scheduled follow-up and with management of toxicity.
- Signed informed consent from patients and/or their parents or legal guardians
Exclusion Criteria:
- Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study
- Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.
- Evidence of pregnancy or lactation period.
- There will be no exclusion criteria based on organ function.
- Past or current anti-cancer treatment except corticosteroids during less than one week.
- Tumor cell negative for CD20
- Prior exposure to rituximab.
- Severe active viral infection, especially hepatitis B.
- Hepatitis B carrier status history of HBV or positive serology.
- Participation in another investigational drug clinical trial.
- Patients who, for any reason, are not able to comply with the national legislation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01516580
Belgium | |
University Hospitals Leuven | |
Leuven, Belgium, 3000 | |
Canada | |
Children Oncology Group Operations centres | |
Monrovia, Canada | |
China | |
The University of Hong Kong (Clinical Trials Centre) | |
Hong-Kong, China | |
France | |
Institut de Cancérologie Gustave roussy | |
Villejuif, France, 94805 | |
Hungary | |
2nd Dept. of Pediatrics Semmelweis Univ. | |
Budapest, Hungary, 1094 | |
Italy | |
Associazione Italiana di Ematologia ed Oncologia Pediatrica | |
Padova, Italy, 35128 | |
Netherlands | |
Emma Children's Hospital | |
Amsterdam, Netherlands, 1105 AZ | |
Poland | |
Rectorat of Medical University | |
Wroclaw, Poland | |
Spain | |
Sociedad Española de Hematología y Oncología Pediátricas | |
Valencia, Spain, 46010 | |
United Kingdom | |
University of Birmingham | |
Birmingham, United Kingdom |
Study Chair: | Véronique MINARD, MD | Institut Gustave Roussy, Villejuif, FRANCE | |
Study Chair: | Thomas GROSS, MD | Children Oncology Group, USA |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Gustave Roussy, Cancer Campus, Grand Paris |
ClinicalTrials.gov Identifier: | NCT01516580 |
Other Study ID Numbers: |
Inter B-NHL Ritux 2010 Phase 3 2010-019224-31 ( EudraCT Number ) |
First Posted: | January 25, 2012 Key Record Dates |
Last Update Posted: | June 14, 2017 |
Last Verified: | June 2017 |
Lymphoma Leukemia Lymphoma, Non-Hodgkin Lymphoma, B-Cell Leukemia, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Hematologic Diseases Leukemia, Lymphoid Chronic Disease |
Disease Attributes Pathologic Processes Cytarabine Cyclophosphamide Rituximab Doxorubicin Liposomal doxorubicin Methotrexate Vincristine Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents |